Vaxcyte’s 24-Valent Pneumococcal Vaccine Shows Best-In-Class Potential
Small Biotech Hopes To Compete In Big Pharma-Dominated Market
The biotech’s share price jumps more than two-thirds as analysts hail top-line Phase I/II data as better than expected. Vaxcyte hopes to hold Phase III planning discussions with the FDA in 2023.
